Prevail Therapeutics Inc. Common Stock
PRVL
PRVL was delisted on the 21st of January, 2021.
42 hedge funds and large institutions have $328M invested in Prevail Therapeutics Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 18 closing their positions.
22% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 18
11% more funds holding
Funds holding: 38 → 42 (+4)
0.47% more ownership
Funds ownership: 77.71% → 78.18% (+0.47%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
6% less capital invested
Capital invested by funds: $349M → $328M (-$21.3M)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$7.03M |
| 2 |
BlackRock
New York
|
+$3.91M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$2.72M |
| 4 |
Bank of New York Mellon
New York
|
+$2.38M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity International
Hamilton,
Bermuda
|
-$6.6M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$3.35M |
| 3 |
Millennium Management
New York
|
-$1.47M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.32M |
PRVL Hedge Fund Activity: Q3 2019 in Review
42 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Prevail Therapeutics Inc. Common Stock (PRVL) for Q3 2019, worth a combined $328M — down 6.1% from $349M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new PRVL positions and 18 closed out — a net gain of 4 holders — while 6 added to existing stakes and 8 trimmed.
The largest buyer was RA Capital Management, adding an estimated $7.03M. The largest seller was Fidelity International, exiting entirely with an estimated $6.6M sold.
- 42 institutional investors held Prevail Therapeutics Inc. Common Stock (PRVL) as of Q3 2019, up from 38 in Q2 2019.
- Funds reported $328M of Prevail Therapeutics Inc. Common Stock stock for Q3 2019, down 6.1% quarter-over-quarter.
- 22 funds opened new Prevail Therapeutics Inc. Common Stock positions in Q3 2019 and 18 closed out, a net change of +4 holders.
- The largest Prevail Therapeutics Inc. Common Stock buyer in Q3 2019 was RA Capital Management, an estimated $7.03M added.
- The largest Prevail Therapeutics Inc. Common Stock seller in Q3 2019 was Fidelity International, an estimated $6.6M sold.
Based on aggregated 13F filings for Q3 2019.